IL158589A0 - Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes - Google Patents

Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Info

Publication number
IL158589A0
IL158589A0 IL15858902A IL15858902A IL158589A0 IL 158589 A0 IL158589 A0 IL 158589A0 IL 15858902 A IL15858902 A IL 15858902A IL 15858902 A IL15858902 A IL 15858902A IL 158589 A0 IL158589 A0 IL 158589A0
Authority
IL
Israel
Prior art keywords
ppar
diabetes
alpha
treatment
carboxylic acid
Prior art date
Application number
IL15858902A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL158589A0 publication Critical patent/IL158589A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15858902A 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes IL158589A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15
PCT/EP2002/004962 WO2002092084A1 (en) 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Publications (1)

Publication Number Publication Date
IL158589A0 true IL158589A0 (en) 2004-05-12

Family

ID=8177436

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15858902A IL158589A0 (en) 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
IL158589A IL158589A (en) 2001-05-15 2003-10-23 Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158589A IL158589A (en) 2001-05-15 2003-10-23 Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators

Country Status (38)

Country Link
US (1) US6642389B2 (enExample)
EP (1) EP1392295B1 (enExample)
JP (2) JP4330883B2 (enExample)
KR (1) KR100654516B1 (enExample)
CN (1) CN100356917C (enExample)
AR (1) AR035892A1 (enExample)
AT (1) ATE327753T1 (enExample)
AU (1) AU2002342244B2 (enExample)
BG (1) BG66316B1 (enExample)
BR (1) BRPI0209821B1 (enExample)
CA (1) CA2445145C (enExample)
CY (1) CY1105160T1 (enExample)
CZ (1) CZ20033037A3 (enExample)
DE (1) DE60211891T2 (enExample)
DK (1) DK1392295T3 (enExample)
EC (1) ECSP034848A (enExample)
EG (1) EG25755A (enExample)
ES (1) ES2264482T3 (enExample)
GT (1) GT200200085A (enExample)
HR (1) HRP20030889B1 (enExample)
HU (1) HU230224B1 (enExample)
IL (2) IL158589A0 (enExample)
JO (1) JO2282B1 (enExample)
MA (1) MA27025A1 (enExample)
ME (1) ME01310B (enExample)
MX (1) MXPA03010435A (enExample)
MY (1) MY136761A (enExample)
NO (1) NO333833B1 (enExample)
NZ (1) NZ529033A (enExample)
PA (1) PA8544901A1 (enExample)
PE (1) PE20021152A1 (enExample)
PL (1) PL208074B1 (enExample)
PT (1) PT1392295E (enExample)
RU (1) RU2278859C2 (enExample)
SI (1) SI1392295T1 (enExample)
SK (1) SK287842B6 (enExample)
WO (1) WO2002092084A1 (enExample)
ZA (1) ZA200308538B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL152979A0 (en) * 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
JP2006514976A (ja) * 2002-11-15 2006-05-18 カディラ ヘルスケア リミティド 置換されているアラルキル誘導体
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
KR100849352B1 (ko) 2003-11-05 2008-07-29 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
MXPA06012683A (es) 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
ES2390620T3 (es) * 2008-03-10 2012-11-14 Nestec S.A. Ácidos dicarboxílicos de cadena mediana y sus derivados y trastornos metabólicos
JP2011520890A (ja) * 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
WO2010072386A2 (en) 2008-12-23 2010-07-01 Roche Diagnostics Gmbh Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
CN102292074B (zh) * 2009-01-23 2013-08-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
EP2585452B1 (en) 2009-12-07 2015-09-23 F.Hoffmann-La Roche Ag Process for the preparation of propionic acid derivatives
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
CA2879500A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
CN109588042A (zh) 2015-11-18 2019-04-05 豪夫迈·罗氏有限公司 用于治疗糖尿病肾病的阿格列扎
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4384507A4 (en) * 2021-08-13 2025-06-18 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
DK1313716T3 (da) * 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета

Also Published As

Publication number Publication date
KR20030096397A (ko) 2003-12-24
RU2003134150A (ru) 2005-06-10
WO2002092084A1 (en) 2002-11-21
SK287842B6 (sk) 2011-12-05
JP4330883B2 (ja) 2009-09-16
DE60211891T2 (de) 2007-05-24
EP1392295B1 (en) 2006-05-31
JO2282B1 (en) 2005-09-12
NO20035086L (no) 2003-11-14
HK1067534A1 (en) 2005-04-15
BG108362A (bg) 2005-03-31
CZ20033037A3 (cs) 2004-06-16
EG25755A (en) 2012-06-26
PL208074B1 (pl) 2011-03-31
HUP0400992A3 (en) 2007-11-28
ECSP034848A (es) 2003-12-24
PA8544901A1 (es) 2003-01-24
HUP0400992A2 (hu) 2004-08-30
HU230224B1 (hu) 2015-10-28
NO20035086D0 (no) 2003-11-14
CA2445145C (en) 2008-10-14
IL158589A (en) 2010-11-30
SK13852003A3 (en) 2004-10-05
HRP20030889A2 (en) 2005-08-31
AU2002342244B2 (en) 2005-06-16
ATE327753T1 (de) 2006-06-15
ME01310B (me) 2011-10-10
MY136761A (en) 2008-11-28
DK1392295T3 (da) 2006-10-02
CY1105160T1 (el) 2009-11-04
SI1392295T1 (sl) 2006-10-31
US6642389B2 (en) 2003-11-04
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
DE60211891D1 (de) 2006-07-06
BR0209821A (pt) 2004-06-01
HRP20030889B1 (hr) 2011-10-31
PT1392295E (pt) 2006-09-29
CA2445145A1 (en) 2002-11-21
EP1392295A1 (en) 2004-03-03
KR100654516B1 (ko) 2006-12-05
CN1509173A (zh) 2004-06-30
NZ529033A (en) 2005-06-24
GT200200085A (es) 2003-01-16
JP2009138011A (ja) 2009-06-25
JP2004529174A (ja) 2004-09-24
BG66316B1 (bg) 2013-04-30
ZA200308538B (en) 2005-04-26
ES2264482T3 (es) 2007-01-01
AR035892A1 (es) 2004-07-21
CN100356917C (zh) 2007-12-26
US20030055265A1 (en) 2003-03-20
NO333833B1 (no) 2013-09-30
PE20021152A1 (es) 2003-02-07
BRPI0209821B1 (pt) 2016-09-27
MXPA03010435A (es) 2004-03-09
MA27025A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
SI1392295T1 (sl) Derivati oksazola, substituirani s karboksilno kislino, za uporabo kot ppar -alfa in -gama aktivatorji pri zdravljenju diabetesa
IL147822A0 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
HUP0401647A3 (en) Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds
IL172170A0 (en) Propionic acid derivatives useful in the treatment of lipid disorders
WO2000045799A3 (de) Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe
ZA200300889B (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia.
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
EP1531806A4 (en) USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED DISEASES
SI1701946T1 (sl) Derivati 1-piperazin- in 1-homopiperazinkarboksilatov, postopek za njihovo pripravo in njihova uporaba kot inhibitorji encima FAAH
AU2002331313A1 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
JO3106B1 (ar) مستحضر صلب يشمل بيوجليتازون وجليمبيريد وإستر حمض دهني لعديد أوكسي إيثيلين سوربيتان
PL375878A1 (en) N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
IL169489A0 (en) Use of derivatives of succinate esters for the treatment of dementia
PL378197A1 (pl) Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii
PL375074A1 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
PL378059A1 (pl) Optycznie czynne pochodne bisoksazoliny, sposób ich wytwarzania i zastosowania
ZA200605302B (en) Use of pentadienoic acid derivatives for the treatment of hyperuricemia
PT1517679E (pt) Derivados do ácido benzóico substituído na posição orto para o tratamento de resistência à insulina
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa
AU2002316940A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
AU2003297807A1 (en) Use of n-chlorotaurine for treatment of oozing tissue deficiencies
AU2003215677A1 (en) N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases
GB9922709D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
EP1539175A4 (en) SUBSTITUTED INDOLALCANIC ACID DERIVATIVES AND FORMULATIONS CONTAINING THEREOF FOR USE IN THE TREATMENT OF DIABETIC COMPLICATIONS
SI1517883T1 (sl) Orto-substituirani derivati benzojske kisline za zdravljenje insulinske rezistence